Dr. Paul Wotton is a serial entrepreneur and inventor with more than 30 years of experience in the biotech and pharma industries. He brings to Combined’s board a strong background in overall business leadership, product development and transformational business transactions. He currently serves on the boards of Vericel, Cynata Therapeutics and Kytopen, and is a co-founder and director of Avenge Bio. Recently, Dr. Wotton was the chief executive officer of Obsidian Therapeutics, where he led fundraising initiatives, built the management team and directed the advancement of an engineered TIL therapy candidate for the treatment of melanoma into its first clinical trial. Before this, he was president and chief executive officer of Ocata Therapeutics until its acquisition by Astellas Pharma. Dr. Wotton serves on the Boards of Directors of Vericel Corporation (NASDAQ: VCEL), Kytopen and Cynata Therapeutics (ASX: CYP) as its Chairman. Until recently, he was a board member at Veloxis Pharmaceuticals A/S (Copenhagen: VELO), which was recently acquired by Asahi. He received his B.Pharm from University College London and his Ph.D. in pharmaceutical sciences from the University of Nottingham.